Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 4/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | RET | P07949 | 1/20 | 0.77 |
| ▸ | KDR | P35968 | 1/20 | 0.77 |
| ▸ | KDM5A | P29375 | 1/20 | 0.77 |
| ▸ | TERT | O14746 | 1/20 | 0.74 |
| ▸ | CREB1 | P16220 | 1/20 | 0.74 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30376285 | 1.00 | MAPT (1.00) | MAPTABCB1EGFRRETKDR | |
| SCHEMBL5792042 | 0.95 | MAPT (0.91) | MAPTABCB1EGFRRETKDR | |
| SCHEMBL14048682 | 0.88 | MAPT (0.78) | MAPTABCB1EGFRRETKDR | |
| SCHEMBL10025658 | 0.87 | MAPT (0.77) | MAPTABCB1EGFRRETKDR | |
| SCHEMBL7306849 | 0.85 | MAPT (0.74) | MAPTABCB1EGFRRETKDR | |
| SCHEMBL8305040 | 0.85 | MAPT (0.73) | MAPTABCB1EGFRRETKDR | |
| SCHEMBL24882669 | 0.85 | EGFR (0.78) | MAPTABCB1EGFRRETKDR | |
| SCHEMBL971995 | 0.85 | CREB1 (1.00) | MAPTABCB1EGFRRETKDR | |
| SCHEMBL28031602 | 0.85 | EGFR (0.74) | MAPTABCB1EGFRRETKDR | |
| SCHEMBL19267888 | 0.84 | L3MBTL1 (0.77) | MAPTABCB1EGFRRETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111836808-B | Novel compound for preventing, alleviating or treating fibrosis or nonalcoholic steatohepatitis and composition comprising the same as active ingredient | 欧斯特奥纽罗根有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-3760626-B1 | NOVEL COMPOUND AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS OR NONALCOHOLIC STEATOHEPATITIS COMPRISING SAME AS ACTIVE INGREDIENT | OSTEONEUROGEN INC (KR) | 2022-05-18 | — | — | EP | disclosed |
| EP-3760626-A1 | NOVEL COMPOUND AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS OR NONALCOHOLIC STEATOHEPATITIS COMPRISING SAME AS ACTIVE INGREDIENT | Osteoneurogen Inc. (KR) | 2021-01-06 | — | — | EP | disclosed |
| CN-111836808-A | Novel compound for preventing, alleviating or treating fibrosis or nonalcoholic steatohepatitis and composition comprising same as active ingredient | 欧斯特奥纽罗根有限公司 | 2020-10-27 | — | — | CN | disclosed |
| US-20190263789-A1 | SUBSTITUTED CHROMENES FOR TREATMENT OF FIBROSIS OR NON-ALCOHOLIC STEATOHEPATITIS | OSTEONEUROGEN INC. (KR) | 2019-08-29 | — | — | US | disclosed |
| US-10370364-B1 | Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis | OSTEONEUROGEN INC. (KR) | 2019-08-06 | — | — | US | disclosed |
| EP-3421035-A1 | NOVEL USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING FIBROSIS BY USING EPITHELIAL-MESENCHYMAL TRANSITION INHIBITORY ACTIVITY THEREOF | Osteoneurogen Inc. (KR) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017146332-A1 | NOVEL USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING FIBROSIS BY USING EPITHELIAL-MESENCHYMAL TRANSITION INHIBITORY ACTIVITY THEREOF | (주)오스티오뉴로젠 | 2017-08-31 | — | — | WO | disclosed |
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | OSTEONEUROGEN INC. (KR) | 2017-08-24 | — | — | US | disclosed |
| EP-2277595-A2 | Compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-7875650-B2 | Baicalein analogs; enhances bioavailability of active compounds, especially orally administered compounds, by inhibition of P-glycoprotein 170 (P-gp 170) and/or CYP450 enzyme; 6-Acetoxy-5,7-dihydroxyflavone | YALE UNIVERSITY (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20070161605-A1 | Compounds and methods to increase anti-p-glycoprotein activity of baicalein by alkylation on the a ring | YALE UNIVERSITY (US) | 2007-07-12 | — | — | US | disclosed |
| WO-2005075449-A1 | COMPOUNDS AND METHODS TO INCREASE ANTI-P-GLYCOPROTEIN ACTIVITY OF BAICALEIN BY ALKYLATION ON THE A RING | YALE UNIVERSITY (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370364-B1 | Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis | CYP7A1, NR1H3, CES1 | MAPT 4809/4885ABCB1 1316/4885EGFR 2317/4885 |
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | MAPT 3668/4885ABCB1 2995/4885EGFR 310/4885 |
| US-20070161605-A1 | Compounds and methods to increase anti-p-glycoprotein activity of baicalein by alkylation on the a ring | ABCB1, ABCB11, ABCG2 | MAPT 4867/4885ABCB1 1/4885EGFR 839/4885 |
| US-20190263789-A1 | SUBSTITUTED CHROMENES FOR TREATMENT OF FIBROSIS OR NON-ALCOHOLIC STEATOHEPATITIS | VIM, HNF4A, CDH1 | MAPT 3277/4885ABCB1 229/4885EGFR 2666/4885 |
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | CDH1, SMAD3, SMAD2 | MAPT 3975/4885ABCB1 527/4885EGFR 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.